Drugs / BYON5667
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04983238 | Jan 2022 → Apr 2023 | breast cancer | Byondis B.V. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BYON5667 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04983238 ↗ |
| Known as | BYON5667: sodium thiosulfate | “BYON5667: sodium thiosulfate” NCT04983238 ↗ |
| Route | Other | “Ocular administration: BYON5667” NCT04983238 ↗ |